Merck Group plans to issue $4 billion in bonds to provide funding for the acquisition of SpringWorks.

According to reports from the Intelligent Finance APP, it has been disclosed by informed sources that Merck KGaA, a German pharmaceutical company, plans to issue approximately $4 billion in investment-grade bonds in the United States to provide funding for its acquisition of SpringWorks Therapeutics. Some informed sources indicated that the bond transaction will be divided into up to four parts with terms of three years, five years, seven years, and ten years. The proceeds from the bond issuance will be used to refinance the $3.9 billion temporary debt incurred for the acquisition of the biopharmaceutical company SpringWorks.